Strategic use of dual regimens of boosted protease inhibitors plus maraviroc in poorly adherent subjects in view of long-acting drugsAmedeo Capetti, Giuliano Rizzardini, Mariangela Micale et al.|Medicine|2017Cited by 3
Durability of Boosted Atazanavir (ATV) or Darunavir (DRV) Plus Maraviroc (MVC) Dual rescue Therapy in Poorly Adherent Subjects in View of Long-Acting DrugsAmedeo Capetti, Giuliano Rizzardini, Simona Landonio et al.|Journal of Antivirals & Antiretrovirals|2017Cited by 1
What impact do the new direct acting antiviral drugs have on the patients’ quality of life?Marta Gentili, Giuliano Rizzardini, C. Magni et al.|Journal of Hepatology|2018Cited by 0
THU-175-Eligibility and feasibility of hepatitis C treatment in the era of direct-acting antiviral agents: Our experience in real-world practiceMonica Schiavini, Giuliano Rizzardini, Simona Landonio et al.|Journal of Hepatology|2019Cited by 0